SCHEMBL14923656

SCHEMBL14923656

Nc1ccc(N2CCOC2=O)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
MAP4K1 Q92918 1/20 0.39
PIM1 P11309 4/20 0.38
OGA O60502 1/20 0.37
MTOR P42345 1/20 0.37
IDH1 O75874 2/20 0.36
EED O75530 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
GRM5 P41594 3/20 0.36
KDM1A O60341 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
TYK2 P29597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411695 0.82 AKR1C3 (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2645587 0.82 MAP4K1 (0.39) MAP4K1PIM1IDH1EEDSUZ12
SCHEMBL13424162 0.82 IDH1 (0.38) MAP4K1PIM1MTORIDH1EED
SCHEMBL9964663 0.82 DGAT1 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27152777 0.80 L3MBTL1 (0.44) MAP4K1
SCHEMBL17221384 0.80 KCNJ1 (0.43) MAP4K1PIM1IDH1EEDSUZ12
SCHEMBL17232492 0.78 HRH3 (0.38) MAP4K1PIM1IDH1EEDSUZ12
SCHEMBL14946762 0.78 DGAT1 (0.43) MAP4K1PIM1IDH1GRM5
SCHEMBL17221105 0.78 VHL (0.38) MAP4K1PIM1EEDSUZ12EZH2
SCHEMBL3375677 0.78 F10 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK GRIN2D 3047/4885GRIN3B 1653/4885GRIN1 790/4885
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GRIN2D 2046/4885GRIN3B 1622/4885GRIN1 940/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK GRIN2D 1067/4885GRIN3B 1196/4885GRIN1 1207/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GRIN2D 2046/4885GRIN3B 1622/4885GRIN1 940/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GRIN2D 2204/4885GRIN3B 1726/4885GRIN1 1041/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GRIN2D 2204/4885GRIN3B 1726/4885GRIN1 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.